Graft Versus Host Disease

8
Pipeline Programs
9
Companies
17
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 6 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
PrografPhase 45 trials
Active Trials
NCT03216447Unknown150Est. Sep 2025
NCT02251691Unknown90Est. Mar 2020
NCT02221583Completed26Est. Feb 2015
+2 more trials
Takeda
TakedaTOKYO, Japan
1 program
1
GLASSIAPhase 2/33 trials
Active Trials
NCT02956122Terminated1Est. May 2018
NCT02722304Terminated7Est. Sep 2018
NCT02525861Completed34Est. Jul 2020
Alliance Pharmaceuticals
1 program
1
AbataceptPhase 21 trial
Active Trials
NCT03924401Active Not Recruiting30Est. Mar 2027
Biogen
BiogenCAMBRIDGE, MA
1 program
1
NatalizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02176031Completed21Est. Feb 2019
Swedish Orphan Biovitrum
1 program
1
PaliferminPhase 2
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01066598Terminated1Est. Aug 2011
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
stem cell transplantPhase 22 trials
Active Trials
NCT00639717Completed48Est. Apr 2016
NCT00501228Terminated2Est. Sep 2008
Novartis
NovartisBASEL, Switzerland
1 program
1
Interleukin-2Phase 11 trial
Active Trials
NCT00529035Completed29Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstellasPrograf
AstellasPrograf
AstellasPrograf
AstellasPrograf
AstellasPrograf
AstellasPrograf
AstellasPrograf
TakedaGLASSIA
TakedaGLASSIA
AstellasPrograf
TakedaGLASSIA
Alliance PharmaceuticalsAbatacept
BiogenNatalizumab
RocheRituximab
Amgenstem cell transplant

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 2,025 patients across 17 trials

A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant

Start: Nov 2017Est. completion: Sep 2025150 patients
Phase 4Unknown

Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant

Start: May 2014Est. completion: Mar 202090 patients
Phase 4Unknown

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy

Start: May 2014Est. completion: Feb 201526 patients
Phase 4Completed

Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation

Start: Apr 2012Est. completion: Jun 201260 patients
Phase 4Completed

A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation

Start: Apr 2011Est. completion: May 2014100 patients
Phase 4Completed

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection

Start: May 2008Est. completion: Mar 20101,252 patients
Phase 4Completed

Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

Start: Feb 2008Est. completion: Feb 201039 patients
Phase 4Completed

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Start: Nov 2016Est. completion: Sep 20187 patients
Phase 3Terminated

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Start: Mar 2016Est. completion: Jul 202034 patients
Phase 3Completed

A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients

Start: Feb 2006Est. completion: Mar 2008135 patients
Phase 3Completed

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Start: Apr 2017Est. completion: May 20181 patients
Phase 2/3Terminated

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

Start: Aug 2019Est. completion: Mar 202730 patients
Phase 2Active Not Recruiting

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Start: Jan 2015Est. completion: Feb 201921 patients
Phase 2Completed

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

Start: May 2010Est. completion: Aug 20111 patients
Phase 2Terminated
NCT00639717Amgenstem cell transplant

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Start: Mar 2009Est. completion: Apr 201648 patients
Phase 2Completed
NCT00529035NovartisInterleukin-2

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Start: Aug 2007Est. completion: May 202029 patients
Phase 1Completed
NCT00501228Amgenstem cell transplant

Tissue Repair in Stem Cell Transplant Recipients

Start: Feb 2003Est. completion: Sep 20082 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 companies competing in this space